Click to expand/collapse Oct 20, 2020
Click to open news item in new windowA New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals' Lead Compound CPI-613®? (devimistat) for Patients With Pancreatic Cancer in Japan

Click to expand/collapse Aug 06, 2020
Click to open news item in new windowRafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ® (devimistat) for Patients with Metastatic Pancreatic Cancer

Click to expand/collapse Jul 21, 2020
Click to open news item in new windowRafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Click to expand/collapse May 26, 2020
Click to open news item in new windowRafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Click to expand/collapse May 08, 2020
Click to open news item in new windowDevimistat Development Progresses in Relapsed/Refractory Burkitt Lymphoma

Click to expand/collapse May 07, 2020
Click to open news item in new windowRafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models

Click to expand/collapse May 05, 2020
Click to open news item in new windowRafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer

Click to expand/collapse Apr 28, 2020
Click to open news item in new windowMD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals' Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt's Lymphoma/Leukemia

Click to expand/collapse Apr 23, 2020
Click to open news item in new windowRafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Click to expand/collapse Mar 24, 2020
Click to open news item in new windowRafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer

   1    2   3